SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (18432)4/1/1998 12:44:00 PM
From: Henry Niman  Respond to of 32384
 
george, thanks for the heads up. The report was also mentioned on the Ligand Yahoo board. I did have trouble finding it. Since it just came out today, it doesn't come up using 'search". As you know, it's located under "commentary" and subscribers can access directly at:
thestreet.com

Ketan Desai is becoming a major LGND ethusiast. He also liked LGND's IL-4 program for Asthma. In the new diabetes treatment area, he wasn't impressed with AMLN's Pramlintide or ERGO's Ergoset, but of course he loves LGND's Targretin!



To: aknahow who wrote (18432)4/1/1998 9:13:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Here's the table from the diabetes review in thestreet.com:
There are 160 compounds in various stages of development (I think they are listed as most advanced or promising :-))

COMPANY NAMES
COMPOUND(S)
ACTION
DEVELOPMENTAL
STAGE
Ligand
(LGND:Nasdaq)
& Lilly
(LLY:NYSE)
Targretin,
LGD 1268,
LGD 1324
Insulin receptor
agonist
Phase III
Alteon
(ALTN:Nasdaq)
& Genentech
(GNE:NYSE)
Pimagedine
Advanced
glycosylation
end product
inhibitor
Phase III
Amylin
(AMLN:Nasdaq)
& Johnson &
Johnson
(JNJ:NYSE)
Pramlintide
"Hormone"
analogue
Phase III
SmithKline
Beecham
(SBH:NYSE
ADR)
Rosiglitazone
Insulin
sensitizer
Phase III
Pfizer
(PFE:NYSE)
Zopolrestat
Aldose
reductase
inhibitor
Phase III
Amgen
(AMGN:Nasdaq)
Leptin
Regulator of
ob(ese) gene
Phase II
AutoImmune
(AIMM:Nasdaq)
AI 401
Oral tolerance
Phase II
Emisphere
(EMIS:Nasdaq)
& Lilly
Insulin
Oral insulin
Phase I
Lilly
LY 333531
Protein kinase
C inhibitor
Phase II
Genzyme
(GENZ:Nasdaq)
GAD
Recombinant
glutamic acid
decarboxylase
Preclinical
Transkaryotic
Therapies
(TKTX:Nasdaq)
Insulin gene
Gene therapy
Preclinical
Pfizer
(PFE:NYSE)
Englitazone
Insulin
sensitizer
Preclinical
Lilly & McGill
and Virginia
Universities
INGAP
Regenerates
islet cells
Preclinical


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News